Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation
Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation
Recruiting · NCT07158710 · Registry updated 2025-09-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation | Malignant Brain Tumors | Recruiting | Phase 1 | 2025-09-08 | NCT07158710 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Haisco Pharmaceutical Group Co., Ltd. | 50 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Department of Neuro-oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University,Beijing, China | Beijing | China | 1 |
| Fudan University Affiliated Huashan Hospital | Shanghai | China | 1 |
| The First Affiliated Hospital of Fujian Medical University | Fuzhou | China | 2 |
| The Third Bethune Hospital of Jilin University | Changchun | China | 1 |
| Xuanwu Hospital Capital Medical University | Beijing | China | 1 |
| Zhujiang Hospital of Southern Medical University | Guangzhou | China | 33 |